Voisin Consulting Life Sciences webinar icon
Webinar

Patient access to Advanced Therapies in Europe 2009-2021: from early access failures to current challenges

Post thumbnail Patient access to Advanced Therapies in Europe 2009-2021: from early access failures to current challenges

The recent announcement of BlueBirdBio to wind down its European commercialisation efforts due to access and pricing challenges for its gene therapy products has put a new spotlight on the market access and payer environment for advanced therapies in Europe.

In this webinar VCLS market access experts analyse the commercial failures of advanced therapies, discuss key HTA challenges for these products in European markets and how to plan ahead to overcome them.

Voisin Consulting Life Sciences download icon

Access the full webinar replay now

Fill in the form to download the content

    Yes, I would like to receive communications regarding VCLS services and events

    Sample of the webinar

    Featured Speakers

    Gabrielle Nayroles
    Gabrielle Nayroles, M.Sc.
    Director, Market Access
    As a Director in the Market Access team, Gabrielle is responsible for conducting market access analyses and providing recommendations and…
    View profile
    Henrike Granzow
    Henrike Granzow, M.Sc.
    Director, Market Access
    As a Director in the Market Access Team, Henrike is responsible for developing successful market access and reimbursement strategies, on…
    View profile
    Emmanuelle Sabbah-Petrover
    Emmanuelle Sabbah-Petrover, PhD
    Director, Complex Biologics
    As Director at Voisin Consulting Life Sciences, Emmanuelle manages projects involving cellular and gene-based medicinal products; from early stages of…
    View profile